1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Asia Pacific Cancer Vaccines Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Asia Pacific Cancer Vaccines Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Asia Pacific Cancer Vaccines Market Regional Analysis
6.2 Asia Pacific Cancer Vaccines Market Revenue 2017-2027 (US$ Million)
6.3 Asia Pacific Cancer Vaccines Market Forecast Analysis
7. Asia Pacific Cancer Vaccines Market Analysis – by Technology
7.1 Dendritic Cells Cancer Vaccines
- 7.1.1 Overview
- 7.1.2 Dendritic Cells Cancer Vaccines: Asia Pacific Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.2 Recombinant Cancer Vaccines
- 7.2.1 Overview
- 7.2.2 Recombinant Cancer Vaccines: Asia Pacific Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.3 Antigen Cancer Vaccines
- 7.3.1 Overview
- 7.3.2 Antigen Cancer Vaccines: Asia Pacific Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.4 Whole Cell Cancer Vaccines
- 7.4.1 Overview
- 7.4.2 Whole Cell Cancer Vaccines: Asia Pacific Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.5 Viral Vector Cancer Vaccines
- 7.5.1 Overview
- 7.5.2 Viral Vector Cancer Vaccines: Asia Pacific Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
8. Asia Pacific Cancer Vaccines Market Analysis – by Type
8.1 Preventive Cancer Vaccines
- 8.1.1 Overview
- 8.1.2 Preventive Cancer Vaccines: Asia Pacific Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.2 Therapeutic Cancer Vaccines
- 8.2.1 Overview
- 8.2.2 Therapeutic Cancer Vaccines: Asia Pacific Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
9. Asia Pacific Cancer Vaccines Market Analysis – by Indication
9.1 Cervical Cancer
- 9.1.1 Overview
- 9.1.2 Cervical Cancer: Asia Pacific Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.2 Prostate Cancer
- 9.2.1 Overview
- 9.2.2 Prostate Cancer: Asia Pacific Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.3 Other Indications
- 9.3.1 Overview
- 9.3.2 Other Indications: Asia Pacific Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
10. Asia Pacific Cancer Vaccines Market Analysis – by End User
10.1 Pediatrics
- 10.1.1 Overview
- 10.1.2 Pediatrics: Asia Pacific Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
10.2 Adults
- 10.2.1 Overview
- 10.2.2 Adults: Asia Pacific Cancer Vaccines Market – Revenue and Forecast, 2017-2027 (US$ Million)
11. Asia Pacific Cancer Vaccines Market – Asia-Pacific Analysis
11.1 Overview
11.2 Asia-Pacific
- 11.2.1 Asia Pacific Cancer Vaccines Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 11.2.1.1 Asia Pacific Cancer Vaccines Market – Revenue and
Forecast Analysis – by Country
- 11.2.1.1 China:
Asia Pacific Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.1.1 China: Asia Pacific Cancer Vaccines Market Breakdown, by Technology
- 11.2.1.1.2 China: Asia Pacific Cancer Vaccines Market Breakdown, by Type
- 11.2.1.1.3 China: Asia Pacific Cancer Vaccines Market Breakdown, by Indication
- 11.2.1.1.4 China: Asia Pacific Cancer Vaccines Market Breakdown, by End User
- 11.2.1.2 India:
Asia Pacific Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.2.1 India: Asia Pacific Cancer Vaccines Market Breakdown, by Technology
- 11.2.1.2.2 India: Asia Pacific Cancer Vaccines Market Breakdown, by Type
- 11.2.1.2.3 India: Asia Pacific Cancer Vaccines Market Breakdown, by Indication
- 11.2.1.2.4 India: Asia Pacific Cancer Vaccines Market Breakdown, by End User
- 11.2.1.3 Japan:
Asia Pacific Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.3.1 Japan: Asia Pacific Cancer Vaccines Market Breakdown, by Technology
- 11.2.1.3.2 Japan: Asia Pacific Cancer Vaccines Market Breakdown, by Type
- 11.2.1.3.3 Japan: Asia Pacific Cancer Vaccines Market Breakdown, by Indication
- 11.2.1.3.4 Japan: Asia Pacific Cancer Vaccines Market Breakdown, by End User
- 11.2.1.4 Australia:
Asia Pacific Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.4.1 Australia: Asia Pacific Cancer Vaccines Market Breakdown, by Technology
- 11.2.1.4.2 Australia: Asia Pacific Cancer Vaccines Market Breakdown, by Type
- 11.2.1.4.3 Australia: Asia Pacific Cancer Vaccines Market Breakdown, by Indication
- 11.2.1.4.4 Australia: Asia Pacific Cancer Vaccines Market Breakdown, by End User
- 11.2.1.5 Rest of Asia-Pacific :
Asia Pacific Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.5.1 Rest of Asia-Pacific : Asia Pacific Cancer Vaccines Market Breakdown, by Technology
- 11.2.1.5.2 Rest of Asia-Pacific : Asia Pacific Cancer Vaccines Market Breakdown, by Type
- 11.2.1.5.3 Rest of Asia-Pacific : Asia Pacific Cancer Vaccines Market Breakdown, by Indication
- 11.2.1.5.4 Rest of Asia-Pacific : Asia Pacific Cancer Vaccines Market Breakdown, by End User
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 AstraZeneca
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 GlaxoSmithKline plc.
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Aduro Biotech Inc
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Pfizer Inc.
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Sanofi
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Bristol-Myers Squibb
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Moderna, Inc.
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 OncBioMune Pharmaceuticals Inc.
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 MaxiVAX
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Nouscom
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations